Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06612268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Name: A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — clinical trial record (NCT06612268)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Hibiscus 2

StatusRecruiting

PhasePhase 3

SponsorNovo Nordisk A/S

Started2025-02-17

View on ClinicalTrials.gov ↗

This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.

Amendment history 1 change detected by DataLookout

2026-08-14

Completion pushed: 2029-03-12 → 2029-08-12

Trial Details

NCT Number	NCT06612268
Lead Sponsor	Novo Nordisk A/S
Conditions	Sickle Cell Disease
Enrollment	408 participants
Start Date	2025-02-17
Primary Completion	2027-08-27 (estimated)
Study Completion	2029-08-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-13